Sabine Amet1, Vincent Launay-Vacher, Olivier Clément, Camille Frances, Aurore Tricotel, Benedicte Stengel, Jean-Yves Gauvrit, Nicolas Grenier, Geneviève Reinhardt, Nicolas Janus, Gabriel Choukroun, Maurice Laville, Gilbert Deray. 1. From the *Service Information Conseil Adaptation Rénale, Department of Nephrology, Hôpital Pitié-Salpêtrière; †Department of Radiology, Hôpital Européen Georges Pompidou; ‡Department of Dermatology, Hôpital Tenon, Paris; §Department of Pharmacovigilance, Agence Nationale de Sécurité du Médicament, Saint-Denis; ∥Department of Inserm U1018, Hôpital Paul Brousse, Villejuif; ¶Department of Radiology, Hôpital Pontchaillou, Rennes; #Department of Radiology, Hôpital Pellegrin, Bordeaux; **Department of Radiology, Hôpital d'Haguenau, Haguenau; ††Department of Nephrology Dialysis and Transplantation and INSERM 1088, Hôpital Sud, Amiens; ‡‡Department of Nephrology, Hôpital Lyon Sud, Lyon; and §§Department of Nephrology, Hôpital Pitié-Salpêtrière, Paris, France.
Abstract
BACKGROUND: Nephrogenic systemic fibrosis (NSF) has been related to the use of gadolinium-based contrast agents (GBCAs) in patients undergoing dialysis. The Prospective Fibrose Nephrogénique Systémique study, a French prospective study supported by the French drug regulatory agency (Agence Nationale de Sécurité du Médicament) and the French Societies of Nephrology, Dermatology, and Radiology, aimed at determining the incidence of NSF in patients undergoing long-term dialysis. MATERIALS AND METHODS: Adult patients undergoing long-term dialysis receiving a magnetic resonance imaging (MRI) examination prescribed between January 15, 2009 and May 31, 2011, with or without GBCA were included. The methodology was based on a patient form intended to detect any dermatological event (DE) that may occur within 4 months after the examination. Further investigations were planned with their physicians if a DE was reported. RESULTS: A total of 571 patients were included. A total of 50.3% received GBCA. Among them, 93.4% received a macrocyclic GBCA, usually gadoteric acid (88.9%). All in all, 22 patients (3.9%) reported a DE. Dermatological diagnoses did not reveal any evidence of NSF. CONCLUSIONS: The incidence of NSF after a single dose of a macrocyclic GBCA is null in our sample of 268 patients undergoing dialysis (hemodialysis and peritoneal dialysis). This incidence is just lower than 0.5%. When contrast-enhanced MRI can be essential, or even decisive, to the diagnosis, these results are important and reassuring if physicians need to perform contrast-enhanced MRI in patients undergoing dialysis.
BACKGROUND:Nephrogenic systemic fibrosis (NSF) has been related to the use of gadolinium-based contrast agents (GBCAs) in patients undergoing dialysis. The Prospective Fibrose Nephrogénique Systémique study, a French prospective study supported by the French drug regulatory agency (Agence Nationale de Sécurité du Médicament) and the French Societies of Nephrology, Dermatology, and Radiology, aimed at determining the incidence of NSF in patients undergoing long-term dialysis. MATERIALS AND METHODS: Adult patients undergoing long-term dialysis receiving a magnetic resonance imaging (MRI) examination prescribed between January 15, 2009 and May 31, 2011, with or without GBCA were included. The methodology was based on a patient form intended to detect any dermatological event (DE) that may occur within 4 months after the examination. Further investigations were planned with their physicians if a DE was reported. RESULTS: A total of 571 patients were included. A total of 50.3% received GBCA. Among them, 93.4% received a macrocyclic GBCA, usually gadoteric acid (88.9%). All in all, 22 patients (3.9%) reported a DE. Dermatological diagnoses did not reveal any evidence of NSF. CONCLUSIONS: The incidence of NSF after a single dose of a macrocyclic GBCA is null in our sample of 268 patients undergoing dialysis (hemodialysis and peritoneal dialysis). This incidence is just lower than 0.5%. When contrast-enhanced MRI can be essential, or even decisive, to the diagnosis, these results are important and reassuring if physicians need to perform contrast-enhanced MRI in patients undergoing dialysis.
Authors: Joseph Lunyera; Dinushika Mohottige; Anastasia-Stefania Alexopoulos; Hilary Campbell; C Blake Cameron; Nicole Sagalla; Timothy J Amrhein; Matthew J Crowley; Jessica R Dietch; Adelaide M Gordon; Andrzej S Kosinski; Sarah Cantrell; John W Williams; Jennifer M Gierisch; Belinda Ear; Karen M Goldstein Journal: Ann Intern Med Date: 2020-06-23 Impact factor: 25.391
Authors: Sean A Woolen; Prasad R Shankar; Joel J Gagnier; Mark P MacEachern; Lisa Singer; Matthew S Davenport Journal: JAMA Intern Med Date: 2020-02-01 Impact factor: 21.873
Authors: Thomas Lauenstein; Francisco Ramirez-Garrido; Young Hoon Kim; Sung Eun Rha; Jens Ricke; Sith Phongkitkarun; Joachim Boettcher; Rajan T Gupta; Pornpim Korpraphong; Wiwatana Tanomkiat; Julia Furtner; Peter S Liu; Maren Henry; Jan Endrikat Journal: Invest Radiol Date: 2015-06 Impact factor: 6.016
Authors: Sebastiano Barbieri; Christophe Schroeder; Johannes M Froehlich; Andreas Pasch; Harriet C Thoeny Journal: Contrast Media Mol Imaging Date: 2016-01-11 Impact factor: 3.161
Authors: Nicola Schieda; Jason I Blaichman; Andreu F Costa; Rafael Glikstein; Casey Hurrell; Matthew James; Pejman Jabehdar Maralani; Wael Shabana; An Tang; Anne Tsampalieros; Christian B van der Pol; Swapnil Hiremath Journal: Can J Kidney Health Dis Date: 2018-06-12
Authors: Henrik J Michaely; Manuela Aschauer; Hannes Deutschmann; Georg Bongartz; Matthias Gutberlet; Ramona Woitek; Birgit Ertl-Wagner; Walter Kucharczyk; Renate Hammerstingl; Francesco De Cobelli; Martin Rosenberg; Thomas Balzer; Jan Endrikat Journal: Invest Radiol Date: 2017-01 Impact factor: 6.016